BRPI0510043A - método de tratamento de dor neuropática usando antagonista de receptor crth2 - Google Patents

método de tratamento de dor neuropática usando antagonista de receptor crth2

Info

Publication number
BRPI0510043A
BRPI0510043A BRPI0510043-7A BRPI0510043A BRPI0510043A BR PI0510043 A BRPI0510043 A BR PI0510043A BR PI0510043 A BRPI0510043 A BR PI0510043A BR PI0510043 A BRPI0510043 A BR PI0510043A
Authority
BR
Brazil
Prior art keywords
receptor antagonist
neuropathic pain
crth2 receptor
treating neuropathic
treating
Prior art date
Application number
BRPI0510043-7A
Other languages
English (en)
Inventor
Laura Corradini
Mark John Field
Ross Anderson Kinloch
Bryn Ivor Williams-Jones
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0408799A external-priority patent/GB0408799D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0510043A publication Critical patent/BRPI0510043A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

MéTODO DE TRATAMENTO DE DOR NEUROPáTICA USANDO ANTAGONISTA DE RECEPTOR CRTH2. A presente invenção refere-se ao uso de um antagonista de receptor de CRTH2 na fabricação de um medicamento para o tratamento de dor neuropática e a um método para tratar dor neuropática utilizando um antagonista de receptor de CRTH2.
BRPI0510043-7A 2004-04-20 2005-04-08 método de tratamento de dor neuropática usando antagonista de receptor crth2 BRPI0510043A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0408799A GB0408799D0 (en) 2004-04-20 2004-04-20 Method of treating pain
US59087104P 2004-07-22 2004-07-22
PCT/IB2005/000992 WO2005102338A1 (en) 2004-04-20 2005-04-08 Method of treating neuropathic pain using a crth2 receptor antagonist

Publications (1)

Publication Number Publication Date
BRPI0510043A true BRPI0510043A (pt) 2007-10-16

Family

ID=34964546

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510043-7A BRPI0510043A (pt) 2004-04-20 2005-04-08 método de tratamento de dor neuropática usando antagonista de receptor crth2

Country Status (7)

Country Link
US (1) US20090170897A1 (pt)
EP (1) EP1740179A1 (pt)
JP (1) JP2007533725A (pt)
BR (1) BRPI0510043A (pt)
CA (1) CA2563707A1 (pt)
MX (1) MXPA06011891A (pt)
WO (1) WO2005102338A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3693258B2 (ja) 1996-07-24 2005-09-07 ワーナー―ランバート・コンパニー イソブチルｇａｂａまたはその誘導体を含有する鎮静剤
MX2007009915A (es) * 2005-02-15 2007-11-06 Elan Pharma Int Ltd Formulaciones en aerosol e inyectables de benzodiazepina nanoparticulada.
MX2007012937A (es) 2005-04-21 2008-03-26 Serono Lab Pirazina-sulfonamidas 2,3-sustituidas.
US8236963B2 (en) 2005-05-24 2012-08-07 Merck Serono Sa Tricyclic spiro derivatives as CRTH2 modulators
GB0525143D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
EP1969117A4 (en) * 2005-12-13 2008-12-17 Trinity Lab Inc METHOD FOR TREATING EARLY EJACULATION IN HUMANS
GB0525337D0 (en) * 2005-12-13 2006-01-18 Novartis Ag Organic compounds
HUE030850T2 (en) 2006-06-16 2017-06-28 Univ Pennsylvania Prostaglandin D2 receptor antagonists for the treatment of hair loss
TR200703092A1 (tr) * 2007-05-08 2008-12-22 SANOVEL �LA� SAN. VE TiC. A.�. Flurbiprofen ve kas gevşetici kombinasyonları
CN101932316A (zh) * 2007-12-21 2010-12-29 Paz医药发展有限公司 药物制剂及其制备和其在治疗疼痛相关的神经病中的应用
SI2250161T1 (sl) * 2008-01-18 2014-04-30 Atopix Therapeutics Limited Spojine, ki imajo aktivnost crth2 antagonista
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
JP2011509991A (ja) 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
US8101645B2 (en) 2008-02-15 2012-01-24 Abbott Laboratories Thienopyrroles and pyrrolothiazoles as new therapeutic agents
EP2396295A1 (en) 2009-02-12 2011-12-21 Merck Serono S.A. Phenoxy acetic acid derivatives
WO2010102154A2 (en) 2009-03-05 2010-09-10 Ligand Pharmaceuticals Incorporated Biaryl oxyacetic acid compounds
WO2011002814A2 (en) 2009-06-30 2011-01-06 Ligand Pharmaceuticals Inc. Biaryl oxyacetic acid compounds
JP5800898B2 (ja) 2010-07-05 2015-10-28 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ １−フェニル−置換ヘテロシクリル誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2794563B1 (en) 2011-12-21 2017-02-22 Actelion Pharmaceuticals Ltd Heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
EP2885307A1 (en) 2012-07-05 2015-06-24 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
CN104634883B (zh) * 2013-11-07 2018-04-27 苏州普源精电科技有限公司 一种具有融合峰基线调整功能的色谱工作站
CN104634906B (zh) * 2013-11-07 2018-07-13 苏州普源精电科技有限公司 分离峰的基线调整方法和具有基线调整功能的色谱工作站
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
GB201407820D0 (en) * 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
WO2016010771A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US20200078351A1 (en) 2015-07-30 2020-03-12 The Trustees Of The University Of Pennsylvania Single nucleotide polymorphic alleles of human dp-2 gene for detection of susceptibility to hair growth inhibition by pgd2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1211513B1 (en) * 1999-08-23 2006-01-04 BML, Inc. Method of identifying modulators of prostaglandin d2 receptors
EP1424335A4 (en) * 2001-09-07 2005-11-16 Ono Pharmaceutical Co INDOLE DERIVATIVES
CA2500582A1 (en) * 2002-10-04 2004-04-22 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
EP1413306A1 (en) * 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as CRTH2 antagonists
DE60305724T2 (de) * 2002-10-21 2006-11-09 Warner-Lambert Co. Llc Tetrahydrochinolin-derivate als crth2 antagonisten
WO2004052863A1 (ja) * 2002-12-06 2004-06-24 Kyowa Hakko Kogyo Co., Ltd. 抗炎症剤
SE0301009D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
US20050038070A1 (en) * 2003-07-09 2005-02-17 Amgen Inc. Asthma and allergic inflammation modulators

Also Published As

Publication number Publication date
WO2005102338A1 (en) 2005-11-03
EP1740179A1 (en) 2007-01-10
WO2005102338A8 (en) 2006-12-14
CA2563707A1 (en) 2005-11-03
US20090170897A1 (en) 2009-07-02
MXPA06011891A (es) 2007-04-24
JP2007533725A (ja) 2007-11-22

Similar Documents

Publication Publication Date Title
BRPI0510043A (pt) método de tratamento de dor neuropática usando antagonista de receptor crth2
BRPI0607402A2 (pt) uso de inibidores de pde7 para o tratamento de dor neuropática
BRPI0810354A2 (pt) Composto, uso de um composto, composição farmacêutica, e, método de tratamento de um dispositivo de dor
BRPI0919876A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para intensificar a qualidade do sono, para tratar insônia, e para tratar ou controlar obesidade em um paciente mamífero que necessita do mesmo.
DE602007011908D1 (de) Verwendung von gpr119-rezeptoragonisten zur vermehrung der knochenmasse und zur behandlung von osteoporose sowie kombinationstherapie dafür
BRPI0717769A2 (pt) Formulação de gel, método para o tratamento da osteoartrite em um indivíduo sofrendo de dor articular, e, uso de diclofenac de sódio
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
BRPI0914902A2 (pt) composição farmacêutica e método para tratamento de mal de parkinson
CY1112889T1 (el) Αναλογα αζετιδινης αναστολεων νουκλεοσιδασης και φωσφορυλασης
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
BRPI0819703A2 (pt) Uso de inibidores de proteína tirosina fosfatase e hormônio de crescimento humano, uso de igf1 e um inibidor de proteína tirosina fosfatase e composição de combinação farmacêutica para o tratamento de atrofia muscular e distúrbios relacionados
BRPI0615157A2 (pt) composto, composição farmacêutica, métodos para inibir a replicação viral em um paciente humano, e para tratar uma infecção viral em um paciente humano, e, uso de um composto
BRPI0514721A (pt) uso de compostos de peptìdeos para tratar dor de cáncer ósseo, dor induzida por quimioterapia e nucleosìdeo
BRPI0510094A (pt) uso de flibanserina no tratamento pré-menstrual e outros distúrbios sexuais femininos
BRPI0607198A2 (pt) composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica
BRPI0820568A2 (pt) Composto, composição farmacêutica, uso de um composto ou uma composição farmacêutica, e, método de tratamento de um humano ou animal
ATE512948T1 (de) Biphenyl-sulfonyl- und phenyl-heteroaryl-sulfonyl-modulatoren des histamin-h3-rezeptors zur behandlung von damit verbundenen erkrankungen
BRPI0815493A2 (pt) Composto, uso de um composto, composição faramcêutica, método para a terapia de dor, e, processo para preparar um composto.
IL189104A (en) Pharmaceutical preparation containing lasalazide or sodium balasalazide for use in the treatment of gastrointestinal disorders.
BRPI0909651A2 (pt) cristal, agente farmacêutico, método para tratar ou evitar doença, uso do cristal, e, método para a produção de um cristal
BRPI0610780A2 (pt) formulação farmacéutica em tablete desintegrante, e, métodos para tratar um paciente em necessidade de tratamento com olanzapina, e para produzir a formulação farmacêutica em tablete
BRPI0520258A2 (pt) uso de uma composição farmacêutica, método para preparar uma composição farmacêutica, e, uso de uma quantidade eficaz de acetato de eslicarbazepina
EP1954800A4 (en) COMPOSITION AND USE OF PHYTO-PERCOLATE FOR THE TREATMENT OF DISEASE
BRPI0921557A2 (pt) bacteriófago filamentoso, primeiro e segundo bacteriófago filamentoso para o uso no tratamento do mal de parkinson, composição farmacêutica, e , método para tratar um paciente

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.